WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that it will present at the 12th Annual Wells Fargo Securities Healthcare Conference at the Westin Waterfront Hotel in Boston, MA. Kala Chairman and Chief Executive Officer, Mark Iwicki will provide a corporate overview and participate in an analyst-led fireside chat on Wednesday, September 6, 2017 at 10:15 AM ET.
To access a live webcast and subsequent archived recording of the presentation, please visit the “Investors & Media” section on the Kala website at http://kalarx.com/.
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to create a corticosteroid designed for ocular applications, resulting in two product candidates in Phase 3 clinical development, KPI-121 1.0% for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.